PURPOSE OF REVIEW: The treatment landscape in advanced and metastatic renal cell carcinoma (RCC) is moving from the inhibition of tyrosine kinases (TKI) and the mammalian target of rapamycin (mTOR) inhibitors to specific immunooncology agents like immune checkpoint inhibitors (ICI). The review focus on the recent immunooncology developments and available trial results within the last 12 months. RECENT FINDINGS: ICI as monotherapy (nivolumab) or immunooncology and immunooncology combinations (nivolumab and ipilimumab) demonstrated positive results on prolonged overall survival in phase III trials. The combination of ICI (atezolizumab) and bevacizumab provided positive signals in prolonged PFS in the PD-L1 positive subgroup. Combinations of ICI and TKI are promising in early phase I and phase II trials. Results are currently expanded in larger phase III studies. The combination of vaccine and TKI in mRCC has not provided beneficial results so far. SUMMARY: The current treatment landscape in mRCC is shifting towards immunooncology agents, which already gained ground in the clinic as ICI monotherapy (nivolumab) or is likely to do in the near future as ICI combination (nivolumab and ipilimumab). The future will hold promise of new combinations with TKIs and ICI or other immunooncology agents like vaccines and metabolic immune checkpoint inhibitors.
PURPOSE OF REVIEW: The treatment landscape in advanced and metastatic renal cell carcinoma (RCC) is moving from the inhibition of tyrosine kinases (TKI) and the mammalian target of rapamycin (mTOR) inhibitors to specific immunooncology agents like immune checkpoint inhibitors (ICI). The review focus on the recent immunooncology developments and available trial results within the last 12 months. RECENT FINDINGS:ICI as monotherapy (nivolumab) or immunooncology and immunooncology combinations (nivolumab and ipilimumab) demonstrated positive results on prolonged overall survival in phase III trials. The combination of ICI (atezolizumab) and bevacizumab provided positive signals in prolonged PFS in the PD-L1 positive subgroup. Combinations of ICI and TKI are promising in early phase I and phase II trials. Results are currently expanded in larger phase III studies. The combination of vaccine and TKI in mRCC has not provided beneficial results so far. SUMMARY: The current treatment landscape in mRCC is shifting towards immunooncology agents, which already gained ground in the clinic as ICI monotherapy (nivolumab) or is likely to do in the near future as ICI combination (nivolumab and ipilimumab). The future will hold promise of new combinations with TKIs and ICI or other immunooncology agents like vaccines and metabolic immune checkpoint inhibitors.
Authors: F Peisen; W Thaiss; N Tietze; S Rausch; B Amend; K Nikolaou; J Bedke; A Stenzl; S Kaufmann Journal: Urologe A Date: 2019-12 Impact factor: 0.639
Authors: Emma L Herbach; Bradley D McDowell; Elizabeth A Chrischilles; Benjamin J Miller Journal: Am J Clin Oncol Date: 2022-07-06 Impact factor: 2.787
Authors: Anna Voelker; Georg Osterhoff; Stefanie Einhorn; Sebastian Ebel; Christoph-Eckhard Heyde; Philipp Pieroh Journal: World J Surg Oncol Date: 2022-06-16 Impact factor: 3.253
Authors: Massimo Ralli; Andrea Botticelli; Irene Claudia Visconti; Diletta Angeletti; Marco Fiore; Paolo Marchetti; Alessandro Lambiase; Marco de Vincentiis; Antonio Greco Journal: J Immunol Res Date: 2020-06-28 Impact factor: 4.818
Authors: Philipp J Stenzel; Mario Schindeldecker; Katrin E Tagscherer; Sebastian Foersch; Esther Herpel; Markus Hohenfellner; Gencay Hatiboglu; Juergen Alt; Christian Thomas; Axel Haferkamp; Wilfried Roth; Stephan Macher-Goeppinger Journal: Transl Oncol Date: 2019-12-24 Impact factor: 4.243
Authors: Maria F Czyzyk-Krzeska; Julio A Landero Figueroa; Shuchi Gulati; John T Cunningham; Jarek Meller; Behrouz ShamsaeI; Bhargav Vemuri; David R Plas Journal: Genes (Basel) Date: 2021-03-09 Impact factor: 4.096